Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D (EVOLUTIONT1D)

4 septembre 2026 mis à jour par: Insulet Corporation

Evaluation Glucose Control Using a Next-Generation Automated Insulin Delivery Algorithm in Individuals With Type 1 Diabetes: EVOLUTION T1D

Feasibility study to evaluate the safety and feasibility of Omnipod automated insulin delivery algorithms in individuals with type 1 diabetes. This study will enroll up to 80 participants to have a minimum of 48 participants to initiate the use of Omnipod. The study will include hotel and outpatient evaluation periods.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Age at time of consent 2-70 years (inclusive)
  • Type 1 diabetes diagnosis for at least 6 months, for those aged 8-70 years, or 3 months for those aged 2-7 years, based on Investigator assessment
  • Basal/Bolus insulin delivery via multiple daily injections or insulin pump with or without automation
  • Willing to use the following types of U-100 insulin during the study: Humalog U-100, Novorapid or their generic equivalents
  • Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
  • If using noninsulin glucose-lowering medications or weight reduction medications, dose has been stable for 6-weeks prior to screening; and participant is willing to not change the dose unless required for safety purposes.
  • Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol
  • Willing to wear the system continuously throughout the study
  • Willing and able to sign the Informed Consent Form (ICF) or has a parent/guardian willing and able to sign the ICF. Assent will be obtained from participants per local regulatory requirements
  • Able to read and understand English
  • If of childbearing potential, willing and able to have pregnancy testing

Exclusion Criteria:

  • Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse.
  • Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or a history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or arrhythmias requiring intervention within the 12 months prior to screening
  • Any planned surgery during the study which could be considered major in the opinion of the Investigator
  • History of more than 1 severe hypoglycaemia in the past 6 months. Severe hypoglycaemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions
  • History of more than 1 diabetic ketoacidosis (DKA) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
  • Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c
  • Use of hydroxyurea
  • Plans to receive blood transfusion over the course of the study
  • Has taken systemic corticosteroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to screening or plans to take oral or injectable steroids during the study
  • Use of non-insulin glucose-lowering medication or weight loss medications other than metformin and/or GLP1, in the 4 weeks prior to screening. Participants taking metformin and/or GLP1 should remain on a steady dose without dose increases during study participation
  • Pregnant or lactating, or is of childbearing potential and not using an acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilisation such as tubal ligation or hysterectomy, or vasectomised partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal).
  • In the past 30-days, has participated in a clinical study using any investigational drug or any investigational device that in the opinion of the investigator may have therapeutic impact on their diabetes management. Additionally, may not intend to participate in any other interventional clinical study during this study period
  • Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment
  • Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Adults with T1D using Omnipod M
Participants will use the Omnipod M System
Expérimental: Adults and pediatrics with T1D using Omnipod S
Participants will use the Omnipod S System

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of time <54 mg/dL
Délai: 72-hour Omnipod M Hotel Period
CGM percent time <54 mg/dL compared to standard therapy
72-hour Omnipod M Hotel Period
Percentage of time <70 mg/dL
Délai: 72-hour Omnipod M Hotel Period
CGM percent time <70 mg/dL compared to standard therapy
72-hour Omnipod M Hotel Period
Percentage of time >180 mg/dL
Délai: 72-hour Omnipod M Hotel Period
CGM percent time >180 mg/dL compared to standard therapy
72-hour Omnipod M Hotel Period
Percentage of time <54 mg/dL
Délai: 4-week Omnipod M outpatient
CGM percent time <54 mg/dL compared to standard therapy
4-week Omnipod M outpatient
Percentage of time <54 mg/dL
Délai: Final 3 weeks of Omnipod S outpatient
CGM percent time <54 mg/dL compared to initial data collection phase
Final 3 weeks of Omnipod S outpatient
Percentage of time <70 mg/dL
Délai: 4-week Omnipod M outpatient
CGM percent time <70 mg/dL compared to standard therapy
4-week Omnipod M outpatient
Percentage of time <70 mg/dL
Délai: Final 3-weeks Omnipod S outpatient
CGM percent time <70 mg/dL compared to initial data collection phase
Final 3-weeks Omnipod S outpatient
Percentage of time >180 mg/dL
Délai: 4-week Omnipod M outpatient
CGM percent time >180 mg/dL compared to standard therapy
4-week Omnipod M outpatient
Percentage of time >180 mg/dL
Délai: Final 3-weeks Omnipod S outpatient
CGM percent time >180 mg/dL compared to initial data collection phase
Final 3-weeks Omnipod S outpatient

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence rate of severe hypoglycemia (SH)
Délai: 72-hour hotel period and 4-week outpatient period
events per person months
72-hour hotel period and 4-week outpatient period
Incidence rate of diabetic ketoacidosis (DKA)
Délai: 72-hour hotel period and 4-week outpatient period
events per person months
72-hour hotel period and 4-week outpatient period
Mean glucose
Délai: 4-weeks Omnipod M outpatient
Mean glucose compared to standard therapy
4-weeks Omnipod M outpatient
Mean glucose
Délai: Final 3-weeks Omnipod S outpatient
Mean glucose compared to initial data collection
Final 3-weeks Omnipod S outpatient
Percentage of time >250 mg/dL
Délai: 4-weeks Omnipod M outpatient
CGM percent time >250 mg/dL compared to baseline
4-weeks Omnipod M outpatient
Percentage of time >250 mg/dL
Délai: Final 3-weeks Omnipod S outpatient
CGM percent time >250 mg/dL compared to initial data collection
Final 3-weeks Omnipod S outpatient
Percentage of time >300 mg/dL
Délai: 4-weeks Omnipod M outpatient
CGM percent time >300 mg/dL compared to standard therapy
4-weeks Omnipod M outpatient
Percentage of time >300 mg/dL
Délai: Final 3-weeks Omnipod S outpatient
CGM percent time >300 mg/dL compared to initial data collection phase
Final 3-weeks Omnipod S outpatient
Percentage of time 70-180 mg/dL
Délai: 4-weeks Omnipod M outpatient
CGM percent time 70-180 mg/dL compared to standard therapy
4-weeks Omnipod M outpatient
Percentage of time 70-180 mg/dL
Délai: Final 3-weeks Omnipod S outpatient
CGM percent time 70-180 mg/dL compared to initial data collection
Final 3-weeks Omnipod S outpatient
Standard Deviation
Délai: 4-weeks Omnipod M outpatient
Standard deviation compared to standard therapy
4-weeks Omnipod M outpatient
Standard Deviation
Délai: Final 3-weeks Omnipod S outpatient
Standard deviation compared to initial data collection
Final 3-weeks Omnipod S outpatient
Coefficient of variation
Délai: 4-weeks Omnipod M outpatient
Coefficient of variation compared to standard therapy
4-weeks Omnipod M outpatient
Coefficient of variation
Délai: Final 3-weeks Omnipod S outpatient
Coefficient of variation compared to standard therapy
Final 3-weeks Omnipod S outpatient
Average total daily insulin (TDI)
Délai: 4-weeks Omnipod M outpatient
Average TDI compared to standard therapy
4-weeks Omnipod M outpatient
Average total daily insulin (TDI)
Délai: Final 3-weeks Omnipod S outpatient
Average TDI compared to initial data collection
Final 3-weeks Omnipod S outpatient
Average TDI/kg
Délai: 4-weeks Omnipod M outpatient
Average TDI/kg compared to standard therapy
4-weeks Omnipod M outpatient
Average TDI/kg
Délai: Final 3-weeks Omnipod S outpatient
Average TDI/kg compared to initial data collection
Final 3-weeks Omnipod S outpatient
Post-prandial glycemic metrics
Délai: Up to 4-hours following tracked meal
Descriptive statistics for CGM metrics during and following meals will be calculated for Omnipod M (hotel) and Omnipod S (outpatient)
Up to 4-hours following tracked meal
Post-exercise session glycemic metrics
Délai: Up to 2-hours following exercise
Descriptive statistics for CGM metrics during and following exercise will be calculated for Omnipod M (hotel) and Omnipod S (outpatient)
Up to 2-hours following exercise
Incidence rate of severe hypoglycemia (SH)
Délai: Final 3-weeks Omnipod S outpatient
events per person months
Final 3-weeks Omnipod S outpatient
Incidence rate of diabetic ketoacidosis (DKA)
Délai: Final 3-weeks Omnipod S outpatient
events per person months
Final 3-weeks Omnipod S outpatient

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

25 mai 2026

Achèvement primaire (Estimé)

31 décembre 2026

Achèvement de l'étude (Estimé)

1 février 2027

Dates d'inscription aux études

Première soumission

11 mai 2026

Première soumission répondant aux critères de contrôle qualité

11 mai 2026

Première publication (Réel)

18 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner